AbbVie Inc. (TSX:ABBV)

Market Cap	552.73B +12.7%
Revenue (ttm)	83.86B +8.6%
Net Income	5.79B -1.2%
EPS	3.24 -1.3%
Shares Out	n/a
PE Ratio	95.39
Forward PE	15.70
Dividend	0.95 (2.94%)
Ex-Dividend Date	Jan 16, 2026

Volume	450
Average Volume	17,665
Open	31.97
Previous Close	32.17
Day's Range	31.54 - 31.97
52-Week Range	23.68 - 34.48
Beta	n/a
RSI	49.85
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD